Characterization of renal biomarkers for use in clinical trials: effect of preanalytical processing and qualification using samples from subjects with diabetes

References

• GuineeDGJrvan ZeeBHoughtonDCClinically silent progressive renal tubulointerstitial disease during cisplatin chemotherapyCancer19937112405040548508369
   PubMed Web of Science ®Google Scholar
• ShemeshOGolbetzHKrissJPMyersBDLimitations of creati nine as a filtration marker in glomerulopathic patientsKidney Int19852858308382418254
   PubMed Web of Science ®Google Scholar
• StarRATreatment of acute renal failureKidney Int1998546181718319853246
   PubMed Web of Science ®Google Scholar
• UchinoSCreatinineCurr Opin Crit Care201016656256720736825
   PubMed Web of Science ®Google Scholar
• DieterleFSistareFGoodsaidFRenal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing ConsortiumNat Biotechnol201028545546220458315
   PubMed Web of Science ®Google Scholar
• HarpurEEnnulatDHoffmanDBiological qualification of bio-markers of chemical-induced renal toxicity in two strains of male ratToxicol Sci2011122223525221593213
   PubMed Web of Science ®Google Scholar
• OzerJSDieterleFTrothSA panel of urinary biomarkers to monitor reversibility of renal injury and a serum marker with improved potential to assess renal functionNat Biotechnol201028548649420458319
   PubMed Web of Science ®Google Scholar
• CookDBrownDAlexanderRLessons learned from the fate of AstraZeneca’s drug pipeline: a five-dimensional frameworkNat Rev Drug Discov201413641943124833294
   PubMed Web of Science ®Google Scholar
• BrottDAAdlerSHAraniRLovickSCPinchesMFurlongSTCharacterization of renal biomarkers for use in clinical trials: bio-marker evaluation in healthy volunteersDrug Des Devel Ther20148227237
   Web of Science ®Google Scholar
• MatheisKLaurieDAndriamandrosoCA generic operational strategy to qualify translational safety biomarkersDrug Discov Today20111613–1460060821570476
   PubMed Web of Science ®Google Scholar
• FuWJLiBLWangSBChanges of the tubular markers in type 2 diabetes mellitus with glomerular hyperfiltrationDiabetes Res Clin Pract201295110510922015481
   PubMed Web of Science ®Google Scholar
• FuWJXiongSLFangYGUrinary tubular biomarkers in short-term type 2 diabetes mellitus patients: a cross-sectional studyEndocrine2012411828821779943
   PubMed Web of Science ®Google Scholar
• HongCYHughesKChiaKSNgVLingSLUrinary alpha 1-microglobulin as a marker of nephropathy in type 2 diabetic Asian subjects in SingaporeDiabetes Care20032633834212547859
   PubMed Web of Science ®Google Scholar
• MatysUBachorzewska-GajewskaHMalyszkoJDobrzyckiSAssessment of kidney function in diabetic patients. Is there a role for new biomarker NGAL, cystatin C and KIM-1?Adv Med Sci201358235336124384771
   PubMed Web of Science ®Google Scholar
• NautaFLBoertienWEBakkerSJGlomerular and tubular damage markers are elevated in patients with diabetesDiabetes Care201134497598121307379
   PubMed Web of Science ®Google Scholar
• PetricaLPetricaMVladAProximal tubule dysfunction is dissociated from endothelial dysfunction in normoalbuminuric patients with type 2 diabetes mellitus: a cross-sectional studyNephron Clin Pract20111182c155c16421150223
   PubMedGoogle Scholar
• ShoreNKhurshidRSaleemMAlpha-1 microglobulin: a marker for early detection of tubular disorders in diabetic nephropathyJ Ayub Med Coll Abbottabad2010224535522455261
   PubMedGoogle Scholar
• SjølieAKPortaMParvingHHBilousRKleinRDIRECT Programme Study GroupThe Diabetic REtinopathy Candesartan Trials (DIRECT) Programme: baseline characteristicsJ Renin Angiotensin Aldosterone Syst200561253216088848
   PubMed Web of Science ®Google Scholar
• SjølieAKKleinRPortaMEffect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomized placebo-controlled trialLancet200837296471385139318823658
   PubMed Web of Science ®Google Scholar
• ChaturvediNPortaMKleinREffect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trialsLancet2008374296471394140218823656
   PubMedGoogle Scholar
• BilousRChaturvediNSjølieAKEffect of candesartan on microalbuminuria and albumin excretion rate in diabetesAnn Intern Med20091511112019451554
   PubMed Web of Science ®Google Scholar
• BenjaminiYHochbergYControlling the False Discovery Rate: A Practical and Powerful Approach to Multiple TestingJournal of the Royal Statistical Society. Series B (Methodological)1995571289300
   Web of Science ®Google Scholar
• AstorBCKöttgenAHwangSJBhavsarNFoxCSCoreshJTrefoil factor 3 predicts incident chronic kidney disease: a case-control study nested within the Atherosclerosis Risk in Communities (ARIC) studyAm J Nephrol201134429129721829008
   PubMed Web of Science ®Google Scholar
• GalantiLMJamartJDell’omoJDonckierJComparison of urinary excretion of albumin, alpha1-microglobulin and retinol-binding protein in diabetic patientsDiabetes Metab19962253243308896994
   PubMed Web of Science ®Google Scholar
• KordonouriOJörresAMüllerCEndersIGahlGMWeberBQuantitative assessment of urinary protein and enzyme excretion – a diagnostic programme for the detection of renal involvement in type I diabetes mellitusScand J Clin Lab Invest19925287817901488617
   PubMed Web of Science ®Google Scholar
• PfleidererSZimmerhacklLBKinneRManzFSchulerGBrandisMRenal proximal and distal tubular function is attenuated in diabetes mellitus type 1 as determined by the renal excretion of alpha 1-microglobulin and Tamm-Horsfall proteinClin Investig19937112972977
   PubMedGoogle Scholar
• NielsenSESchjoedtKJAstrupASNeutrophil Gelatinase-Associated Lipocalin (NGAL) and Kidney Injury Molecule 1 (KIM1) in patients with diabetic nephropathy: a cross-sectional study and the effects of lisinoprilDiabet Med2010271011471150
   Web of Science ®Google Scholar
• WaltonCBodanskyHJWalesJKForbesMACooperEHTubular dysfunction and microalbuminuria in insulin dependent diabetesArch Dis Child19886332442492451477
   PubMed Web of Science ®Google Scholar
• MauerSMSteffesMWBrownDMThe kidney in diabetesAm J Med19817036036127011015
   PubMed Web of Science ®Google Scholar
• ThomasMCBurnsWCCooperMETubular changes in early diabetic nephropathyAdv Chronic Kidney Dis200512217718615822053
   PubMed Web of Science ®Google Scholar
• HongCYChiaKSMarkers of diabetic nephropathyJ Diabetes Complications199812143609442815
   PubMed Web of Science ®Google Scholar
• KordonouriOKahlAJörresAHopfenmüllerWMülerCDanneTThe prevalence of incipient tubular dysfunction, but not of glomerular dysfunction, is in creased in patients with diabetes onset in childhoodJ Diabetes Complications1999135–632032410765010
   PubMed Web of Science ®Google Scholar
• YuHYanagisawaYForbesMACooperEHCrocksonRAMacLennanICAlpha-1-microglobulin: an indicator protein for renal tubular functionJ Clin Pathol1983362532596186698
   PubMed Web of Science ®Google Scholar